1-3
2026
影响因子区间
—
平台估算
66%
2025
中国作者发文占比
—
收费
期刊简介:Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
【译文】抗癌药物报道了与抗癌药物相关的临床和实验结果,欢迎关于抗癌药物设计、药物递送、药理学、激素和生物模式以及化疗评估的贡献。Anti-Cancer Drugs是一本致力于快速发表针对癌症治疗剂的创新研究的国际同行评审期刊,旨在刺激和报道关于有毒和无毒抗癌剂的研究。因此,该期刊的范围将涵盖传统的细胞毒性化疗以及激素或生物反应模式,如白细胞介素和免疫疗法。提交的文章将由编辑进行初步审查。一些文章可能会在没有进一步考虑的情况下退回给作者。那些被考虑发表的文章将接受进一步的评估和同行评审。

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q3 | 暂无 |
| 影响因子区间 | 1-3 | 暂无 |